[
    [
        {
            "time": "2018-04-03",
            "original_text": "[强于大市评级]医药行业政策点评：国务院发布仿制药框架政策 看好国内优质药企进口替代及行业集中度提升机会",
            "features": {
                "keywords": [
                    "仿制药",
                    "框架政策",
                    "进口替代",
                    "行业集中度"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "[强于大市评级]医药行业政策点评：国务院发布仿制药框架政策 看好国内优质药企进口替代及行业集中度提升机会",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-05",
            "original_text": "[强于大市评级]医药生物行业点评：国务院出台鼓励仿制药文件 国产仿制药迎来春天",
            "features": {
                "keywords": [
                    "仿制药",
                    "国产",
                    "春天"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "[强于大市评级]医药生物行业点评：国务院出台鼓励仿制药文件 国产仿制药迎来春天",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-06",
            "original_text": "免疫疗法点燃抗癌新希望 6股获机构扎堆推荐",
            "features": {
                "keywords": [
                    "免疫疗法",
                    "抗癌",
                    "机构推荐"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "免疫疗法点燃抗癌新希望 6股获机构扎堆推荐",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-07",
            "original_text": "[推荐评级]医药行业重点公司2018年一季报业绩前瞻：聚焦一季报 关注创新+升级主线",
            "features": {
                "keywords": [
                    "一季报",
                    "创新",
                    "升级"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[推荐评级]医药行业重点公司2018年一季报业绩前瞻：聚焦一季报 关注创新+升级主线",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-08",
            "original_text": "[看好评级]医药行业事件点评：国务院仿制药政策点评：从仿制药大国走向仿制药强国",
            "features": {
                "keywords": [
                    "仿制药",
                    "政策",
                    "强国"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "[看好评级]医药行业事件点评：国务院仿制药政策点评：从仿制药大国走向仿制药强国",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-09",
            "original_text": "[推荐评级]医药行业2018年4月份投资月报暨Q2季度策略：创新+升级 从初春到盛夏",
            "features": {
                "keywords": [
                    "创新",
                    "升级",
                    "Q2策略"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[推荐评级]医药行业2018年4月份投资月报暨Q2季度策略：创新+升级 从初春到盛夏",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-10",
            "original_text": "生物医药行业:《关于改革完善仿制药供应保障及使用政策的意见》出台,国内优质仿制药企业受益",
            "features": {
                "keywords": [
                    "仿制药",
                    "政策",
                    "优质企业"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "生物医药行业:《关于改革完善仿制药供应保障及使用政策的意见》出台,国内优质仿制药企业受益",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]